Banco Santander (SAN)
(Real Time Quote from BATS)
$4.74 USD
-0.01 (-0.21%)
Updated Jul 9, 2024 01:20 PM ET
1-Strong Buy of 5 1
B Value F Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SAN 4.74 -0.01(-0.21%)
Will SAN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SAN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SAN
SAN or SMFG: Which Is the Better Value Stock Right Now?
Best Income Stocks to Buy for July 9th
SAN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Value Stocks to Buy for July 5th
Should Value Investors Buy Banco Santander (SAN) Stock?
Banco Santander (SAN) Upgraded to Buy: Here's Why
Other News for SAN
Assured Guaranty, Kymera rise; BP, Helen of Troy fall, Tuesday, 7/9/2024
Major mortgage lenders in UK chopping rates as competition heats up
EU approves Sanofi drug Dupixent for chronic lung disease
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
GLOBAL BROKER RATINGS: Redburn raises Siemens Energy to 'buy'